MAP4K3

Across TCGA pan-cancer cohorts, MAP4K3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP4K3 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP4K3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP4K3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, GBM, and UCEC are the cancer types where MAP4K3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.449	0.191	.002	11	view →
GBM	OS	Median	All	0.215	0.534	.005	10	view →
UCEC	DFS	Median	II,III,IV	0.880	0.520	.034	6	view →
CCRCC	OS	Median	III,IV	0.985	0.237	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP4K3–PDAC (DFS)

Open the PDAC breakdown →